368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors
Adi Diab(Cleveland Clinic), Sandra P. D’Angelo(Memorial Sloan Kettering Cancer Center), Mann Muhsin(Nektar Therapeutics (United States)), Brendan D. Curti(Providence Portland Medical Center), Andrew S. Brohl(Moffitt Cancer Center), Mehmet Asım Bilen(Emory Healthcare), Mario Q. Marcondes(Nektar Therapeutics (United States)), Mona Vimal(Nektar Therapeutics (United States)), Evidio Domingo‐Musibay(University of Minnesota), Erkut Borazanci(HonorHealth), Mary Tagliaferri(Nektar Therapeutics (United States)), Christie Fanton(Nektar Therapeutics (United States)), Anh Duy Nguyen(Nektar Therapeutics (United States)), Cat M. Haglund(Allogene Therapeutics (United States)), Wei Lin(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States))
Cited by 15
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
|Journal of Clinical Oncology|2015|1.1k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816